Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease

Health-tech startup Clinikk opens 18 primary care centers across Bengaluru and Hyderabad

Clinikk has raised $6.4 Million so far from marquee investors such as MassMutual Ventures, 500 Startups, Times Internet and prominent angels like Kunal Shah, Rohit MA, Rajan Anandan etc.

Dabur launches 'Dabur Himalayan Shilajit'

Evonik launches non-animal-derived collagen platform for medical device applications

Fermentation-based manufacturing leverages Evonik’s biotechnology platform

Apollo Hospitals Navi Mumbai performs first minimally invasive mitral heart valve replacement

Transcatheter Mitral valve procedure allows intervention on patients who are unsuitable or high risk for open heart surgery

Atik Cameras launches ChemiMOS for long exposure imaging

Atik Cameras launches ChemiMOS; A 9MP CMOS camera for scientific applications

GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer

Healthcare is timely and personal – and its delivery should be too

Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital

The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.

Dapagliflozin met primary endpoint in DELIVER Phase III trial

Results from the DELIVER and DAPA-HF Phase III trials demonstrate Dapagliflozin’ efficacy in heart failure regardless of ejection fraction

Sarclisa (isatuximab) combination provides unprecedented median progression-free survival

The median progression free survival, increased from 19.2 months to 35.7 months when Sarclisa was added to carfilzomib and dexamethasone